New Modality Oral Biologics Platform For Treatment Of GI Disorders
Bioengineered Probiotic Yeast Medicines (BioPYM)
Fzata's vision : Reduce health inequities by expanding patient access to therapeutic biologics.
Our oral biologics for gastrointestinal (GI) disorders will:
improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules
improve patient compliance with no needles and no health-care administrated infusion
improve chronic use outcomes given the high safety profile, no ADA, no systemic tox.
The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) platform empowers orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.
Utilizing BioPYM, we have a deep preclinical pipeline of oral biologics to treat GI-related disorders.
BioPYM Platform Potential in Multiple GI Indications
We’re happy to hear from you. Contact us today to learn more about
the live yeast biotherapeutics BioPYM platform and benefits working with us.
Fzata, Inc. 1450 S. Rolling Rd, Room 4.097, Halethorpe, Maryland 21227 USA